Welcome to our dedicated page for Bayer Aktien news (Ticker: BAYRY), a resource for investors and traders seeking the latest updates and insights on Bayer Aktien stock.
BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer (OTC:BAYRY) named Kacy Perry as Country Division Head for Crop Science Canada, effective July 1. She will lead 550+ employees across multiple Canadian sites and join the North American Leadership Team.
Perry succeeds Antoine Bernet and brings extensive experience from marketing, product management, and sales leadership roles.
Bayer (OTC:BAYRY) completed the acquisition of Perfuse Therapeutics, fully integrating the company and obtaining full rights to PER-001, an intravitreal implant in Phase II development for Glaucoma and Diabetic Retinopathy.
Bayer paid an upfront USD 300 million, with total potential deal value up to USD 2.45 billion, including success-based milestones. The acquisition is intended to strengthen Bayer’s pharmaceutical pipeline and ophthalmology franchise.
Aleve (OTC:BAYRY) launched its Project DIY campaign under the Feel Aleve platform, featuring HGTV’s Dave and Jenny Marrs and other DIY creators. The initiative highlights Aleve’s claim of up to 12 hours of body pain relief from one dose, helping hobbyists stay focused on home projects.
The campaign began in May and will run through summer 2026 across social, digital, and Walmart retail channels. According to Aleve, 28% of pain relief buyers view home improvement as a hobby, a key insight behind this marketing push.
Bayer (OTC:BAYRY) received FDA approval for AMBELVIST (gadoquatrane), a macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity in the CNS and non-CNS body regions in adults and pediatric patients, including term neonates.
AMBELVIST is dosed at 0.01 mmol/kg (0.04 mmol Gd/kg), using 60% less gadolinium than mGBCAs at 0.1 mmol Gd/kg and 20% less than gadopiclenol at 0.05 mmol Gd/kg. Phase III QUANTI studies supported efficacy and safety. The product carries a Boxed Warning for intrathecal use and nephrogenic systemic fibrosis and is contraindicated in patients with prior severe hypersensitivity to AMBELVIST.
Bayer (OTC:BAYRY) appointed Dr. Jost Reinhard as President of its Radiology business within the Pharmaceuticals Division, effective August 1, 2026. He will report to Stefan Oelrich and succeeds Nelson Ambrogio, who became President of Bayer U.S. Pharmaceuticals in May 2026.
Reinhard brings over 25 years of healthcare experience at Bayer across R&D, commercial roles in multiple countries, investor relations, and leadership of the Cell and Gene Therapy unit.
Bayer (OTC:BAYRY) announced global Consumer Health leadership changes on June 8, 2026 to support its Road to Billions growth strategy. The moves target faster decisions, stronger commercial execution, and expanded use of data.
New leaders include a global CMO, CDO, CCO, and a new U.S. Consumer Health President.
Bayer (OTC:BAYRY) reported full Phase III FIND-CKD results for KERENDIA (finerenone) in 1,584 adults with non-diabetic chronic kidney disease on standard of care. KERENDIA improved eGFR slope versus placebo (−3.3 vs −4.0 mL/min/1.73 m²/year; difference 0.7; p<0.001) and reduced a composite kidney-cardiovascular outcome (HR 0.77; 95% CI 0.60–0.99; p=0.043). Safety was generally similar, with serious adverse events 20.9% vs 21.2%. Hyperkalemia occurred in 17% vs 13.3%, with serious hyperkalemia <1% in both groups.
Bayer (OTC:BAYRY) will present new investigational data on KERENDIA (finerenone) at the 63rd European Renal Association Congress, June 3‑6, 2026, in Glasgow.
Highlights include first full Phase III FIND‑CKD results in non‑diabetic CKD and initial INFINITY pooled analysis across diabetic and non‑diabetic CKD populations.
Bayer (OTCMKTS:BAYRY) reported Phase II ARACOG head-to-head data showing patients on NUBEQA (darolutamide) had significantly less cognitive decline than those on enzalutamide over 24 weeks.
Median maximal cognitive decline in the primary endpoint MCCD was -15.8% with NUBEQA versus -36.1% with enzalutamide (p=0.009).
Bayer (OTC:BAYRY) will present new oncology data at the ASCO 2026 Annual Meeting in Chicago, May 29–June 2.
Sixteen abstracts cover prostate, breast, lung, salivary gland, renal cell, and colorectal cancers, including Phase II ARACOG results for NUBEQA and multiple studies of XOFIGO, HYRNUO, VITRAKVI, and STIVARGA.